Fig. 5.
![Fig. 5. Treatment of the BCL1 lymphoma with RIT late in the disease. Groups of 10 mice were given 106 cells on day 0 as usual and then left until day 14 before treating IV with radioiodinated MoAb (750 μg/animal [approximately 7.5 MBq]). The treatments included: Control IgG (⋆); control IgG2a (⧫); anti-Id (□, ▪); anti-MHC II (TI2-3; ○, •); and anti-MHCII (N22; ▿, ▾). The solid and open symbols represent MoAb labeled with and without radioactive iodine, respectively. Surprisingly the131I–anti-Id MoAb provided long-term protection to all the mice.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/94/1/10.1182_blood.v94.1.233.413a25_233_243/6/blod41325005x.jpeg?Expires=1735840161&Signature=nRszpPM-YQ04cFeEI1KlNu6nEIcXsKDnxhQKtisfRqe~p2lN4QS4Vk4fYIAA~lWWUv4eCvlXJAsu0dSGOR2gZKxtjP9M2-WMZeE1is5tJNOE8kzLDj467ZyI-cTZV392aPBZnj~dCzblOlv5lgsAW1tU9EXlDmaNMyqaIgV~SebdRXcrU50iWvHlUlHZdL46kBLH1xK70C7~5w2ViPHDo6vyBNK6UdnLHwbPauOKeJn9im-h3lKNwpj~emca~r22dwaujGNqsnEoCDcuF2IZhMqQFnUpC7Gm6T6GfIJf9K0pSf0h8sCEaEC~Vly5y5TC63Itmwz-kCnQLT41-lW6aQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment of the BCL1 lymphoma with RIT late in the disease. Groups of 10 mice were given 106 cells on day 0 as usual and then left until day 14 before treating IV with radioiodinated MoAb (750 μg/animal [approximately 7.5 MBq]). The treatments included: Control IgG (⋆); control IgG2a (⧫); anti-Id (□, ▪); anti-MHC II (TI2-3; ○, •); and anti-MHCII (N22; ▿, ▾). The solid and open symbols represent MoAb labeled with and without radioactive iodine, respectively. Surprisingly the131I–anti-Id MoAb provided long-term protection to all the mice.
